radioconjugates

Radioconjugates are molecules that combine a biologically active targeting agent with a radioactive isotope. The targeting agent, which could be a peptide, antibody, or small molecule, is designed to specifically bind to a particular target, such as a receptor or antigen that is overexpressed on diseased cells. The radioactive isotope, often a gamma emitter or positron emitter, acts as a detectable tracer. When administered to a patient, the radioconjugate travels through the body and the targeting agent directs the radioactive isotope to the desired location. This allows for imaging of the target site using techniques like Positron Emission Tomography (PET) or Single-Photon Emission Computed Tomography (SPECT).

Beyond diagnostics, radioconjugates can also be used for therapy. In this case, the radioactive isotope is chosen for its therapeutic radiation emission properties, such as alpha or beta particles, which can kill cells. This form of therapy is known as radiopharmaceutical therapy. The targeted delivery of radiation minimizes damage to healthy tissues, making it a promising approach for treating various diseases, particularly cancer. The development of radioconjugates involves careful selection of both the targeting moiety and the radionuclide, as well as optimization of the conjugation chemistry to ensure stability and efficacy.